Abstract: The present disclosure provides a massaging device. The massaging device includes a plurality of massaging implements and at least one sleeve member adapted to encompass the plurality of massaging implements and forms an abutting configuration. Further, a housing member is configured to engage a massaging area on a user. The housing member is adapted to enclose the sleeve member encompassing the massaging implements, wherein each of the member is aligned along an internal axis of the housing member. The housing member ensures that massaging implements in the sleeve member is adapted to roll along a direction perpendicular to the internal axis and resist rolling along the direction of the internal axis upon application of a force during a massaging event. The device provides a stable platform for the user, thereby mitigating manual intervention of the user for holding the device during the massaging event.

Abstract: A drumming device for delivering a repetitive percussive strike to muscles below a skin surface comprises a main housing enclosing an electric motor with a shaft having a fixed rotational speed, a drive pulley, a toothed belt encircling the drive pulley and a driven pulley with an integral cam mounted on said pulley such that the rotating shaft causes the driven pulley to rotate at a predetermined number of cycles per second, the assembly causing a repetitive, reciprocal movement of a plunger body a fixed distance and at 16.6 cycles/sec, said plunger movable in a downward direction following contact with the cam, such that the plunger reciprocates within said housing when said cam member contacts the plunger causing the plunger shaft to move laterally outward. When the massaging device is properly position in contact with the skin the moving plunger causes muscle spindles to vibrate at their resonant frequency.

Abstract: Integrated devices for performing external chest compression (ECC) and defibrillation on a person and methods using the devices. Integrated devices can include a backboard, at least one chest compression member operably coupled to the backboard, and a defibrillator module operably coupled to the backboard. The integrated devices can include physiological sensors, electrodes, wheels, controllers, human interface devices, cooling modules, ventilators, cameras, and voice output devices. Methods can include defibrillating, pacing, ventilating, cooling, and performing ECC in an integrated, coordinated, and/or synchronous manner using the full capabilities of the device. Some devices include controllers executing methods for automatically performing the coordinated activities utilizing the device capabilities.

Abstract: An apparatus (1) for providing cardiopulmonary resuscitation by applying compressions to a chest of a patient (P). The apparatus (1) comprising a chest compression unit (10), in particular comprising automatic actuation, at least one band (20) to be passed around the patient's chest for maintaining the chest compression unit (10) in position on the patient's chest. At least one end of the band (20) is releasably connectable to the unit (10) or another band. The apparatus (1) is designed for pushing the band (20) underneath the patient's chest, in particular on the side where the patient contacts the ground (G). The apparatus (1) comprises or is connectable to an application aid (30), in functional connection with the band (20), fixable to or movable relative to the band and adapted to support pushing the band (20) underneath the patient's chest. The application aid is stiffer than the band.

Abstract: An elevation device used in the performance of cardiopulmonary resuscitation (CPR) and after resuscitation includes a base and an upper support operably coupled to the base. The upper support is configured to incline at an angle relative to the base to elevate an individual's upper back, shoulders and head. The elevation device includes a support arm coupled with the upper support. The support arm is movable to various positions relative to the upper support and is lockable at a fixed angle relative to the upper support such that the upper support and the support arm are movable as a single unit relative to the base while the support arm maintains the angle relative to the upper support. The elevation device also includes a chest compression device coupled with the support arm. The chest compression device is configured to compress the chest.

Abstract: A method of increasing blood flow to the head includes causing an individual's blood to circulate while the individual's heart and head are at a first elevation position, elevating the individual's heart and head to a second elevation position that is above the first elevation position, and causing the individual's blood to circulate while the individual's heart and head are at the second elevation position.

Abstract: A perforating needle intended to be inserted into a flask through a stopper or septum to inject and remove a fluid includes a pointed end for piercing the stopper and a cylindrical body. The central body includes a central channel through which the fluid may enter and leave the flask and a side wall having at least one lateral orifice. The orifice is in fluid communication with the central channel. A lower end of the orifice is, in use, essentially level with an inner face of the stopper. The orifice is extended toward the pointed end by at least one slot, a shape of which is essentially tangential to a flow of the fluid so as to channel the fluid along an axis of the needle. The side wall includes at least two diametrically opposite lateral orifices arranged on either side of a central island.

Abstract: A needle-less vial assembly that includes a substance transfer assembly configured to telescopically engage with a vial neck of a vial. A first portion of the substance transfer assembly is configured to sealingly engage with an interior wall of the vial neck, where the first portion includes a first inlet configured to receive a substance from the vial. A second portion of the substance transfer assembly is configured to matingly engage with a syringe, and includes an outlet configured to dispense the substance to the syringe. A channel is defined through the first portion and the second portion, thereby enabling fluid communication of the substance from the vial to the syringe via the first inlet and the outlet.

Abstract: Various systems and methods for the pressure-regulated transfer of medical fluids are disclosed. The system can include an adapter assembly that connects with a medical container and with a syringe assembly. The syringe assembly can include a first reservoir and a second reservoir. In various embodiments, when the adapter assembly and the syringe assembly are coupled, the first reservoir and the container can exchange regulating fluid and the second reservoir and the container can exchange medical liquid from the medical container.

Abstract: A transporting device for an automated drug-dosing device, and in particular to a transporting device for feeding individual portions of drugs, which allows rapid cleaning of the device, is provided. The transporting device includes at least one transporting tray with a plurality of upwardly open accommodating compartments which are arranged in a single plane and are intended for accommodating one or more individual portions of drugs. The transporting device also includes a carrying frame accommodating the at least one transporting tray, wherein the at least one transporting tray is arranged in a removable manner in the carrying frame and each accommodating compartment has a base opening. The carrying frame includes a closing device with at least one closing plate, wherein base openings of the at least one transporting tray being arranged in a single plane, can be freed, and closed, by movement of the at least one closing plate relative to the at least one transporting tray.

Abstract: Disclosed is a medication dispensing tray adapter for attachment to a medication dispensing tray, the tray adapter having a slidable overlapping foil layer to incrementally expose the compartments of the medication dispensing tray. The tray and tray adapter may be combined into a medication dispenser apparatus that delivers the medication dispensed from the tray compartments to the patient.

Abstract: This invention relates to a dosage management system that comprises a container including a box with an opening towards the top. The box has a first side with an opposing second side and a third side. The box has a pair of parallel grooves in the first side and second side and a tray inside the box. There is also provided a resilient sliding lid. The lid has two parallel opposing edges that slidingly engage the grooves. At least one of the edges and grooves has a catch and notch combination that engage when the lid is in a closed position. The grooves have a first incline or decline part connected to a substantially horizontal part which is again connected to a second incline or decline part. When opening the box, the lid is pushed down the lid then bending into the horizontal part, the notch and catch disengaging and the lid is moved to the third side to open the box.

Abstract: Methods and apparatus for an enteral feeding pump system. A method of directing flow for a coil includes drawing fluid from a source and delivering fluid, the coil including input and output check valves to prevent a back flow of fluid.

Abstract: A saliva collection apparatus including a funnel-shaped saliva collection unit having an upwardly extended substantially trapezoidal lip. A cane-shaped earpiece has a hooked upper portion, a linear middle portion continuously attached to the hooked upper portion, and an L-shaped bottom portion having an upper end and a lower end rotatably and removably attached to an exterior surface of the saliva collection unit. A flexible tube has a top end attached within a funnel opening of the saliva collection unit and a bottom end. A disposable flexible collection bag is removably attached to the bottom end of the tube.

Abstract: The invention relates to nano-sized complexes formed by associating or attaching amorphous calcium phosphate (ACP) and/or amorphous calcium fluoride phosphate (ACFP) with an amphiphilic polymer surfactant (APS) and a bioadhesive polymer. The bioadhesive polymer may serve as a connector or an anchor to attach the nano ACP-APS or ACFP-APS to the tooth surface and to chemically bond the calcium in the enamel to the calcium ions in the nano ACP-APS or ACFP-APS complexes, thus allowing for more controlled release of remineralizing components into the oral cavity. Methods of use of the composition and kits are also disclosed.

Abstract: The present disclosure is directed to a composite structure that is generally planar in shape. The composite structure has one or more layers; at least one of the layers includes one or more types of fibers. In one aspect, the present disclosure is directed to a composite structure including a hydrophobic support layer and a hydrophilic reservoir layer. The hydrophilic reservoir layer includes a composition that is liquid at temperatures below 30-35 degrees Celsius and that is a hydrogel at temperatures above 30-35 degrees Celsius. In order to better control the phase change of the composition and, therefore, to insulate the hydrophilic reservoir layer from warmth, the hydrophobic support layer may have a thermal conductivity that is 5 to 30 times less, in watts per meter kelvin, than water.

Abstract: The present disclosure relates to a cosmetic agent for lightening keratin fibers, which contains two separate powder-formed preparations (A) and (B), each of which is packaged in a water-soluble film, and a method for lightening keratin fibers using the agent. The cosmetic agent of the present disclosure does not require the use of free hydrogen peroxide.

Abstract: Multi-functional base emulsions that can be used to form a variety of cosmetic compositions are disclosed. In one aspect, a cosmetic emulsion can include a water phase including about 10% to about 67.5% water by total weight of the cosmetic emulsion. The cosmetic emulsion can also include an oil phase that includes (a) stearalkonium hectorite, and (b) a silicone alkyl polyether selected from the group consisting of: PEG/PPG-18/18 dimethicone, PEG/PPG-20/15 dimethicone, and Lauryl PEG/PPG-18/18 dimethicone.

Abstract: Described herein are oral care compositions comprising (i) a magnesium alkali metal silicate complex clay, and (ii) an orally acceptable anionic polymer, in a dentifrice base, which compositions are useful for alleviating dental sensitivity. Also provided for, are methods of making and using the compositions described herein.

Abstract: A cosmetic having excellent properties in transparency, spreadability, smoothness, skin compatibility and safety is prepared using a synthetic talc that is flake-like particles containing 2:1-type laminar crystals of silicate which have a basic structure of an octahedron sheet sandwiched between two tetrahedron sheets. The flake-like particle has a mean volume particle diameter of 0.5 to 100 ?m, and 0.3° or less of half width at half maximum of peak present at 2? equal to 9.4°±1° when measured by unoriented powder X-ray diffractometry (XRD) using CuK? rays, and the cosmetic is substantially free of Mg3Si2O5(OH)4.

Abstract: An abrasive type silica with low refractive index and high transparency, a preparation method and an application thereof are disclosed. The preparation method of the present invention includes the following steps: S1, a sodium sulfate solution is added into a reaction tank, the solution is heated to 80-95° C., a sodium silicate solution and a sulfuric acid solution are added at the same time while stirring, the dropping rate of the sodium silicate solution is controlled at 13-15 m3/h, the dropping rate of the sulfuric acid solution is controlled to ensure that the pH value of the reaction process is 3.0-4.5, and stirring is continued for 10-15 min after the adding is finished; and S2, the formed silica is filter pressed, washed, spray-dried and airflow crushed to prepare the abrasive type silica with low refractive index and high transparency.

Abstract: Provided herein is an aqueous composition comprising an active antiperspirant ingredient and disodium EDTA, wherein the active antiperspirant ingredient is present in an amount of 0.2 weight % to 3 weight % by total weight of the composition on an anhydrous basis, wherein the active antiperspirant ingredient comprises an aluminum salt, and wherein the pH of the composition is from 2 to 5. The composition may be used as an antiperspirant when applied to the axillary area of a person.

Abstract: Moisturizers including an acyl neutral amino acid having an acyl group with a carbon atom number of 2 to 18, and salts thereof, and cosmetics containing such a moisturizer promote the production of moisturizing-related proteins, such as filaggrin, involucrin, transglutaminase 1, keratin 10, and loricrin, and provide a moisturizing effect.

Abstract: An oral care composition comprising zinc phosphate, stannous fluoride, arginine or lysine and an organic acid buffer system, as well as methods of using the same.

Abstract: Provided is a topical formulation comprising (1) three or more of the following four components a through d, or (2) component c and one or more of components a, b or d: (a) a skin barrier repair formulation comprising fatty acid, bilayer-stabilizing steroid, and complex lipid (CL), wherein the weight ratio of CL to steroid is from about 1.5:1 to about 8:1, and the weight ration of CL to FA is from about 4:1 to about 1:1, the lipids present in an amount from about 3% wt. to about 10% wt.; (b) a natural moisturizer formulation, wherein the natural moisturizers are urea, urocanic acid, pyrrolidone-5-carboxylic acid, lactic acid or free amino acid; (c) one or more retinoids in an amount from about 0.01% wt. to about 10% wt.; or (d) taurine in an amount from about 0.1% wt. to about 5% wt.

Abstract: The disclosure relates to agents for dyeing keratin fibers, in particular human hair, containing, in a cosmetic carrier (a) at least one direct dye of formula (I), wherein Het1, Het2 represent cationic heterocycles; R1, R3 respectively represent a substitute which is not hydrogen, and Q represents a grouping of formula (VIII), (IX), or (X).

Abstract: The present invention relation to an oral care composition comprising an ionic liquid wherein the ionic liquid comprises: (a) a pyrazolium cation and (b) an anion selected from the group consisting of acetate, halide, phosphate, alkyl phosphate, sulphate, alkyl sulphate and tosylate is provided.

Abstract: The invention relates to a skin anti-ageing composition. In particular a skin anti-ageing composition comprising myricetin or glycoside thereof, and at least one LXR alpha agonist. By skin ageing is meant the appearance or manifestation of any one or more of wrinkles or sagging, poor skin barrier such as dryness, scalp itch, or uneven skin tone such as age spots.

Abstract: The present invention relates to a method for producing a transparent or semi-transparent liquid glycerin derivative-modified silicone composition that comprises a hydration step of adding water to a liquid glycerin derivative-modified silicone or composition thereof. The present invention can provide a liquid glycerin derivative-modified silicone composition having a transparent or semi-transparent appearance can be provided.

Abstract: A composition for providing a film on keratin fibers, the composition comprising: an aminosilicone polymer; a silicone resin; an ether of a water-soluble polyhydric alcohol; a thickening system comprising a deposition enhancer and a thickening polymer; one or more colored materials or one or more pigments; water; and a volatile alcohol. Also, associated methods, kits and uses.

Abstract: The present invention discloses a hair conditioner composition comprising a) from about 0.15% to about 16% moisture control material or mixtures of moisture control materials wherein one or more moisture control material is selected from the group containing: i. Class I Moisture Control Material having the structure selected from: wherein R? is —COOY, sulfonic acid, or —C?CH—COOY, Y is hydrogen or a metal ion, R1, R2, R3, R4, R5 is hydrogen, methyl, ethyl, propyl, vinyl, allyl, methoxy, ethoxy, hydroxyl, halogen, sulfate, sulfonate, nitro, or —CH?CH—COOR, and wherein the moisture control material is an acidic material and further wherein the moisture control material has a % Protein binding higher than 20 and Molecular Volume lower than 500 and Partition coefficient octanol to water (log P) lower than 3 and hydrogen binding higher than 10 and pKa lower than 5.0; ii.

Abstract: Compositions and methods useful for maintaining the structural integrity of keratin in the presence of hair bleaching agents and coloring dyes are disclosed. The compositions provide a significant improvement in minimizing hair breakage while improving hair conditioning, smoothness and styling.

Abstract: The present invention relates to a skin care composition comprising an extract of Bursera simaruba seeds and a cosmetically acceptable topical carrier. Such composition is useful for improving skin barrier function and moisturization as well as improving signs of skin aging.

Abstract: Cosmetic, pharmaceutical or dietary composition comprising an extract of the bacteria Arthrobacter agilis, preferably rich in carotenoids.

Abstract: An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Abstract: A contraceptive drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a contraceptive agent over an extended time period. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods of using the drug delivery system, including in female contraception, are also provided.

Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.

Abstract: The present invention provides processes for the production of a submicron oil in water emulsion comprising the steps: a. preparing a submicron oil in water emulsion; b. pre-filtering the oil in water emulsion; c. filtering the oil in water emulsion filtered according to step b) through a sterile grade filter; d. filtering the oil in water emulsion filtered according to step c) through a filter separate to that of step b) or step c); and e. filtering the oil in water emulsion filtered according to step d) through a sterile grade filter separate to that of steps b), c) and/or d).

Abstract: A pharmaceutical dosage form which comprises a lactide, glycolide or lactide-glycolide polymer, a block polymer of polyglycolide, trimethylene carbonate, poly-caprolactone, and polyethylene oxide that is combined with a peptide or protein therapeutic agent in the form of microparticles which are compressed using a pressure of 50,000 to 350,000 psi.

Abstract: Disclosed are methods for hydration of ST-246 particles comprising exposing said particles to moisture by conveying volumes of air containing moisture.

Abstract: The present application relates to a method for the preparation of a nanosuspension comprising nanoparticles of at least one natural material and an extract of at least one natural material, wherein the method comprises the steps of providing particles of at least one natural material having a particle size (D100) of less than 320 ?m; providing an extract of at least one natural material; dispersing said particles of at least one natural material and said extract of at least one natural material in a solvent; and milling the dispersion to a particle size (D90) of below 1000 nm (D90<1000 nm). Furthermore, the present application also relates to a nanosuspension prepared according to said method, and the use of such nanosuspension for the preparation of a medicament and/or nutritional supplement.

Abstract: Pharmaceutical formulation in the form of agglomerates comprising A) an excipient content composed of a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of a disintegrant, c) 1-15% by weight of water-insoluble, film-forming polymers d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients the total of the components a) to e) being 100% by weight, and B) at least one active ingredient.

Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.

Abstract: Provided is a base material for dry direct tableting, the material being excellent in a binding property and disintegrability. More specifically, provided is a method of preparing a composite granule comprising at least a step of granulating a second sugar or sugar alcohol while adding thereto an aqueous dispersion comprising at least low-substituted hydroxypropyl cellulose having a degree of hydroxypropoxy substitution of 5 to 16% by weight, polyvinyl alcohol, a first sugar or sugar alcohol, and water.

Abstract: Novel thyroid hormone oral dosage forms and methods of making and using the thyroid hormone oral dosage forms are disclosed.

Abstract: Provided is a nanoparticle-vitreous body-based protein complex, and more particularly, to a composition for inhibiting angiogenesis which includes the complex as an active ingredient, and a composition for preventing or treating an angiogenesis-related disease or a retinal disease. When the nanoparticle-vitreous body-based protein complex according to the subject matter is locally injected into the vitreous body, the complex exhibits significantly excellent binding strength with a vascular endothelial growth factor and thus can inhibit angiogenesis, thus being easily used to prepare a therapeutic agent for preventing, alleviating, or treating retinal and choroidal angiogenesis-related diseases.

Abstract: The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.

Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36? (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

Abstract: A method for producing an antibiotic-loaded transdermal patch including preparing a polymeric adhesive solution by dissolving a polymeric mixture in a solvent, preparing a plurality of antibiotic-loaded solid lipid nanoparticles (SLNs), forming a patch formulation by mixing the plurality of antibiotic-loaded SLNs and the polymeric adhesive solution, and forming a layer of the patch formulation on a substrate.